A Study of Hairy Cell and Other Leukemias With a Focus on Recombinant Immunotoxins for Cancer Treatment

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: \- Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers. The investigators are particularly interested in samples from individuals who have diseases that can be treated with a new type of drug called immunotoxin, in which an antibody carrying a toxin binds to a cancer cell and allows the toxin to kill the cell.

Objectives: \- To collect a variety of clinical samples, including blood, urine, lymph samples, and other tissues, in order to study the samples and develop new treatments for leukemia.

Eligibility: \- Individuals 18 years of age and older who have been diagnosed with leukemia or other kinds of blood and lymphatic system cancers, or who are healthy volunteers.

Design: * Individuals who have leukemia will be asked to provide blood, bone marrow, urine, and tumor tissue samples as requested by the researchers. Healthy volunteers will provide only blood and urine samples. * No treatment will be given as part of this protocol.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

‣ All participants

⁃ 18 years of age and older

⁃ Desire of the individual to submit data and samples for research

⁃ Ability to understand and the willingness to sign a written informed consent document.

‣ Individuals with cancer

• Participants may have a diagnosis of hematologic malignancy or solid tumor. These participants would not be excluded if they were in long-term complete remission.

‣ Normal donors (Individuals without cancer)

• Individuals must not have a current or prior diagnosis of a hematologic malignancy or solid tumor.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Julie C Feurtado, R.N.
julie.feurtado@nih.gov
(301) 480-6186
Backup
Robert J Kreitman, M.D.
kreitmar@mail.nih.gov
(301) 648-7375
Time Frame
Start Date: 2010-03-02
Participants
Target number of participants: 1263
Treatments
1
Patients with hematologic malignancies or solid tumors.
2
Normal Donors who are defined as individuals without a diagnosis of or history of any cancer.
Sponsors
Leads: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials